VeriSIM Life announced that it has entered into a partnership agreement with Total Brain to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Brain's proprietary mental health and brain performance database with VeriSIM Life's BIOiSIM™ AI-enabled drug development decision engine to enable new psychiatric and neurological therapies. The Total Brain platform helps more than one million individuals improve overall mental health and brain performance using several semi-quantitative functional methods.

The company's data sets represent the larger standardized brain database encompassing human electrical brain function, brain structure and blood flow, inclusive of full genetic assessments. With this partnership, the BIOiSIM platform will utilize its Translational Index to discover novel drug candidates with other capabilities such as: Evaluate efficacy and side effects of existing drugs and novel drug candidates used to treat various neurological conditions in specific patient subpopulations with differing genetic, biomarker and demographic profiles, Develop highly differentiated patient stratification strategies, Help biotechnology companies develop genetics prediction products related to neurological diseases, Develop companion diagnostics tracking essential biomarker data during the development of new drugs treating neurological diseases.